Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study
A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second submission for a molecule already unde...
A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second submission for a molecule already under review by the FDA.